Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report?Zacks Investment Research • 09/02/26
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026GlobeNewsWire • 08/28/26
CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?The Motley Fool • 08/21/26
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/03/26
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial ResultsGlobeNewsWire • 08/03/26
CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to ConsiderZacks Investment Research • 07/30/26
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?The Motley Fool • 07/30/26
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 07/27/26
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should KnowZacks Investment Research • 07/24/26
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are UnderratingThe Motley Fool • 07/22/26
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for InvestorsZacks Investment Research • 07/17/26
CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key FactsZacks Investment Research • 07/10/26
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR TherapeuticsThe Motley Fool • 07/08/26
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?The Motley Fool • 07/07/26
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 07/06/26